Patents by Inventor Jane Fridlyand

Jane Fridlyand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8404829
    Abstract: Cancer markers may be developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genes in the human chromosomal regions, 8q24, 11q13, 20q11-q13, were found to be amplified indicating in vivo drug resistance in diseases such as ovarian cancer. Diagnosis and assessment of amplification levels certain genes shown to be amplified, including PVT1, can be useful in prediction of poor outcome of patient's response and drug resistance in ovarian cancer patients with low survival rates. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically ovarian cancer. Therapeutics to inhibit amplification and inhibitors of one of these genes, PVT1, target drug resistance in ovarian cancer patients with low survival rates is described.
    Type: Grant
    Filed: January 19, 2006
    Date of Patent: March 26, 2013
    Assignees: The Regents of the University of California, The Board of Regents, University of Texas System
    Inventors: Joe W. Gray, Yinghui Guan, Wen-Lin Kuo, Jane Fridlyand, Gordon B. Mills
  • Publication number: 20120077694
    Abstract: Cancer markers are developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genome wide analyses of genome copy number and gene expression in breast cancer revealed 66 genes in the human chromosomal regions, 8p11, 11q13, 17q12, and 20q13 that were amplified. Diagnosis and assessment of amplification levels of genes shown to be amplified are useful in prediction of patient outcome of a of patient's response and drug resistance in breast cancer. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically breast cancer. Inhibitors of these genes will be useful therapies for treatment of these non-responsive cancers.
    Type: Application
    Filed: September 23, 2011
    Publication date: March 29, 2012
    Applicant: The Regents of the University of California
    Inventors: Joe W. Gray, Jane Fridlyand, Richard Neve, Paul Spellman, Koei Chin, Zhi Hu, Frederic Waldman
  • Publication number: 20110183336
    Abstract: Methods of-identifying a basal or luminal phenotype of a cell, comprising detecting expression of one or more of a set of predictive biomarker genes or proteins that identify the cell as having a basal or luminal cancer subtype and compositions for treating identified basal or luminal cancers.
    Type: Application
    Filed: April 26, 2010
    Publication date: July 28, 2011
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: JOE W. GRAY, DEBOPRIYA DAS, WEN-LIN KUO, NICHOLAS J. WANG, RICHARD M. NEVE, PAUL T. SPELLMAN, JANE FRIDLYAND, KOEI CHIN, ZHI HU
  • Publication number: 20090203051
    Abstract: Cancer markers are developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genome wide analyses of genome copy number and gene expression in breast cancer revealed 66 genes in the human chromosomal regions, 8p11, 11q13, 17q12, and 20q13 that were amplified. Diagnosis and assessment of amplification levels of genes shown to be amplified are useful in prediction of patient outcome of a of patient's response and drug resistance in breast cancer. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically breast cancer. Inhibitors of these genes will be useful therapies for treatment of these non-responsive cancers.
    Type: Application
    Filed: December 8, 2008
    Publication date: August 13, 2009
    Applicant: The Regents of the University of California
    Inventors: Joe W. Gray, Jane Fridlyand, Richard Neve, Paul Spellman, Koei Chin, Zhi Hu, Frederic Waldman
  • Publication number: 20080312096
    Abstract: Cancer markers may be developed to detect diseases characterized by increased expression of apoptosis-suppressing genes, such as aggressive cancers. Genes in the human chromosomal regions, 8q24, 11q13, 20q11-q13, were found to be amplified indicating in vivo drug resistance in diseases such as ovarian cancer. Diagnosis and assessment of amplification levels certain genes shown to be amplified, including PVT1, can be useful in prediction of poor outcome of patient's response and drug resistance in ovarian cancer patients with low survival rates. Certain genes were found to be high priority therapeutic targets by the identification of recurrent aberrations involving genome sequence, copy number and/or gene expression are associated with reduced survival duration in certain diseases and cancers, specifically ovarian cancer. Therapeutics to inhibit amplification and inhibitors of one of these genes, PVT1, target drug resistance in ovarian cancer patients with low survival rates is described.
    Type: Application
    Filed: January 19, 2006
    Publication date: December 18, 2008
    Applicant: The Regents of the University of California
    Inventors: Joe W. Gray, Yinghui Guan, Wen-Lin Kuo, Jane Fridlyand, Gordon B. Mills